



Published in final edited form as:

Curr Opin Crit Care. 2017 April ; 23(2): 143–148. doi:10.1097/MCC.0000000000000386.

New insights into the gut as the driver of critical illness and organ failure

Mei Meng¹, Nathan J. Klingensmith², and Craig M. Coopersmith²

¹Department of Critical Care Medicine, Shandong Provincial Hospital Affiliated Shandong University, Jinan, China

²Department of Surgery and Emory Center for Critical Care, Emory University School of Medicine, Atlanta, GA

Abstract

Purpose of review—The gut has long been hypothesized to be the “motor” of multiple organ dysfunction syndrome (MODS). This review serves as an update on new data elucidating the role of the gut as the propagator of organ failure in critical illness.

Recent findings—Under basal conditions, the gut absorbs nutrients and serves as a barrier that prevents approximately 40 trillion intraluminal microbes and their products from causing host injury. However, in critical illness, gut integrity is disrupted with hyperpermeability and increased epithelial apoptosis, allowing contamination of extraluminal sites that are ordinarily sterile. These alterations in gut integrity are further exacerbated in the setting of pre-existing co-morbidities. The normally commensal microflora is also altered in critical illness, with increases in microbial virulence and decreases in diversity, which leads to further pathologic responses within the host.

Summary—All components of the gut are adversely impacted by critical illness. Gut injury can not only propagate local damage, but can also cause distant injury and organ failure.

Understanding how the multifaceted components of the gut interact and how these are perturbed in critical illness may play an important role in turning off the “motor” of MODS in the future.

Keywords

gut; critical illness; apoptosis; permeability; dysbiosis

Introduction

For the past 30 years, the gut has been hypothesized to be the “motor” of MODS (1). The original theory was straightforward – critical illness induces hyperpermeability, leading to translocation of intact bacteria into the systemic circulation, with subsequent sepsis and organ failure. While this theory remains attractive in conception and is likely correct in select clinical scenarios, reality is significantly more complex.

Address correspondence to: Craig M Coopersmith, 101 Woodruff Circle, Suite WMB 5105, Atlanta, GA 30322, Phone: (404) 727-4273, Fax: (404) 727-3660, cmcoop3@emory.edu.

The gut is comprised of three interlocking components – the epithelium, the microbiome and an immune system. The sheer magnitude of these helps underscore the complexity contained within the gut. The surface area of the gut epithelium is half the size of a badminton court (2). The gut lumen contains approximately 40 trillion bacterial cells, a similar number of cells as the entire host contains (3). Finally, the gut contains over 80% of the lymphocytes in the entire host (4). Despite the enormity of connections within the gut, under basal conditions, all of its components interact with each other to play a crucial role in maintaining host health.

Each component of the gut, however, is markedly perturbed in critical illness. At the bedside, this can be recognized as an ill-defined syndrome called “gut failure,” where critically ill patients often have a constellation of symptoms including absent bowel sounds, diarrhea, abdominal distension, vomiting, high tube feeding residuals, gastrointestinal bleeding due to stress ulceration and intra-abdominal hypertension. While none of these alters prognosis by itself, the presence of three or more of these symptoms on the first day in an ICU stay is associated with a three-fold increase in mortality (5). Further, elevated intestinal fatty acid binding protein (a marker of enterocyte damage) and decreased citrulline (a marker of enterocyte mass) are also associated with mortality in the intensive care unit (6;7).

This review will highlight recent advances in the molecular and cellular pathophysiology of the gut in disease that have, in turn, led to a more refined understanding of how the gut can propagate both local and distant organ dysfunction. Of note, it is currently not practical to obtain tissue samples from the gut epithelium or immune system of most critically ill patients, so preclinical studies are generally required to yield many of the new insights described below. It is, however, possible to obtain stool and/or rectal swabs from critically ill patients allowing investigators a new way of studying the gut in critical illness in humans.

The gut epithelium – providing nourishment and acting as the Great Wall of the body

The human host receives nearly all of its nutrients and is simultaneously protected from trillions of potential microbial invaders by a single cell layer epithelium. At the base of the intestinal crypt, multipotent stem cells actively proliferate and give rise to daughter cells. These cells differentiate as they migrate up the villus to absorptive enterocytes, mucus-producing goblet cells and enteroendocrine cells. When cells reach the villus tip, they die by apoptosis or are exfoliated whole into the gut lumen. The entire journey from cell birth to migration/differentiation to death occurs in under a week.

The gut provides an enormous absorptive surface area of approximately 32m² (2). It also provides a semi-permeable physical barrier, limiting bacterial and molecular particulate infiltration. Permeability, in turn, is controlled by tight junction proteins between each cell that regulate the paracellular space. All elements of gut integrity are impacted by critical illness. Both sepsis and severe non-infectious inflammation (trauma, burns, hemorrhage, etc.) induce a marked increase in gut epithelial apoptosis with a simultaneous decrease in crypt proliferation (8;9). This leads to shortened villus length, decreased absorptive capacity,

alterations in systemic inflammation and increased paracellular permeability. Notably, restoration of gut integrity is beneficial in pre-clinical models of critical illness as intestine-specific overexpression of either the anti-apoptotic protein Bcl-2 or the pro-growth/pro-survival mediator Epidermal Growth Factor improves survival in murine models of both peritoneal sepsis and pneumonia (10;11).

Critical illness is also associated with intestinal hyperpermeability. Alterations in selected tight junction proteins can be identified as early as 1 hour after the onset of murine sepsis, and worsened gut barrier persists for a minimum of 48 hours in models of cecal ligation and puncture (CLP, a model of fecal peritonitis), as well as *Pseudomonas aeruginosa* pneumonia (12). Sepsis-induced gut hyperpermeability is associated with increased jejunal claudin 2 and Junctional Adhesion Molecule-A expression as well as decreased claudin 5 and occludin expression. Further, colonic tight junctions are also altered in rodent sepsis with increased claudin 2 and alterations in cellular localization of claudins 1, 3, 4, 5, and 8 (13).

While factors deleterious to the host can exit the gut into the systemic circulation, an alternate route is via the mesenteric lymph (14). Gut-derived lymph travels directly to the pulmonary circulation and ligating the mesenteric lymph duct prevents lung injury and mortality in burn, trauma, and shock in both large and small animal studies. Highlighting that gut-derived critical illness is not as simple as bacterial translocation, post-shock mesenteric lymph in rats subjected to trauma/hemorrhagic shock does not contain any 16s rRNA genetic material (of bacterial origin), but does contain an increase in damage associated molecular pattern material (15), suggesting that mesenteric lymph transports pro-inflammatory mediators that are distinct from bacteria to propagate systemic inflammation.

Comorbid conditions

As the age of precision medicine is dawning, it has become apparent that patients respond very differently to similar insults. While some of the differences in host response are assuredly genetically based, others result from a lifetime accumulation of environmental insults and chronic disease states. It is well accepted that pre-existing co-morbidities are associated with increased mortality in critical illness. As an example, a data set of 6.6 million patients from Denmark from 1996–2014 demonstrated that alcohol abuse, diabetes mellitus, cardiovascular diagnoses, and cancer are associated with increased mortality following sepsis compared to baseline (16).

Gut integrity is worsened by numerous co-morbidities. The presence of pre-existing lung cancer prior to the onset of CLP induces a further decrease in crypt proliferative capacity compared to previously healthy animals subjected to the same septic insult, and this is associated with increased mortality (17). Similarly, the presence of pre-existing pancreatic cancer prior to the onset of *Pseudomonas aeruginosa* pneumonia induces an increase in gut epithelial apoptosis above and beyond what could be expected from either insult in isolation (18).

Gut integrity is also worsened when mice drink alcohol for 12 weeks prior to sepsis induction via CLP. Alcohol/septic mice have increased gut permeability, epithelial apoptosis

and decreased crypt proliferation and villus length compared to previously healthy septic mice, and this is associated with increased mortality (19). Notably, when alcohol-fed septic animals are given Epidermal Growth Factor, it improves both intestinal integrity and survival to levels seen in water-fed septic animals. However, its efficacy in sepsis is blunted in the setting of chronic alcohol ingestion, since gut integrity and mortality in alcohol-fed septic mice given Epidermal Growth Factor does not approach that in water-fed septic mice given the same agent (20).

Aging also impacts gut integrity. Aged septic mice have a disproportionate increase in gut epithelial apoptosis, compared to what could be predicted with either age or sepsis in isolation (21). The impact of age in targeting gut integrity appears to be complex. For example, 8–10 week old mice with a conditional, intestine-specific deletion of microsomal triglyceride transfer protein have a complete block in chylomicron assembly with lipid malabsorption. When these young mice are made septic via *Pseudomonas aeruginosa* pneumonia, they are protected against sepsis-induced increases in gut apoptosis and decreases in proliferation and villus length, and this is associated with improved survival (22). In contrast, aged (20–24 month) mice of the same genotype have increased gut apoptosis following sepsis with increased Bax/Bcl-2 and Bax/Bcl-X_L ratio, and this is associated with worsened mortality (23).

The gut microbiome

The microbiome begins forming its symbiotic relationship with the host starting at birth and continues to evolve throughout life (24). While the term microbiome refers to all microorganisms residing within (mouth, lungs, gut) or on (skin) the host, the majority of bacterial species and diversity of the microbiome reside within the gut lumen. Over 1000 different bacterial species make up the gut microbiome, containing over 2 million genes (3;25). The majority of gut microbes fall within two phyla: *Firmicutes* and *Bacteroidetes*, and the ratio between these changes over life with a relative increase in the former in the elderly (26;27).

Under basal conditions, the microbiome plays a crucial role in host health. However, critical illness leads to multiple changes to the microbiome, including loss of diversity and overgrowth of pathogenic bacteria (28). These changes are frequently exacerbated by antibiotic usage and by unrelated therapies such as proton pump inhibitors which impact the microbiome nonetheless. Notably, the transition from a healthy microbiome to a pathobiome occurs within hours of a number of varied insults including sepsis, trauma and burns (29). While the mechanisms underlying this transition are still being determined, it appears the host environment causes not only a change in the relative abundance of bacterial species present but also an alteration of their virulence factors. For example, when *Pseudomonas aeruginosa* is injected into the cecum of mice subjected to sham surgery and then harvested and implanted into the peritoneum of uninjured mice, it does not cause any mortality. However, when the same microbe is injected into the cecum of mice subjected to 30% hepatectomy and then harvested and implanted into the peritoneum of uninjured mice, all recipient mice die (30). This suggests that an alteration in the host environment is sensed by bacteria, which, in turn, alter their virulence factors to become pathogenic.

Given the dysbiosis of the gut microbiome in critical illness, modulating the endogenous flora for therapeutic benefit has drawn significant attention (31;32). This can be done by either giving or stimulating growth of presumptively beneficial microbes (probiotics, prebiotics, synbiotics) or eliminating presumptively detrimental microbes via selective decontamination of the digestive tract. A newer approach to dysbiosis is transplanting an intact microbiome via fecal microbiota transplantation (FMT). FMT has been proven to be highly successful in the setting of recurrent *Clostridium difficile* colitis (33;34). In addition, FMT has been successful in case reports of critically ill patients with dysbiosis-induced diarrhea not caused by *Clostridium difficile* (35;36). However, the utility of FMT in critically ill patients has practical limits posed by the need to avoid antibiotic usage, as giving antimicrobial agents to a patient would be expected to immediately alter the transplanted microbiome. Ultimately, although each of these strategies to target the gut microbiome in critical illness is supported by both a theoretical rationale and varying degrees of evidence, none of these currently represent standard of care worldwide.

Immune system

Given the constant exposure of the gut to external microbial antigens, the immune system plays a critical role in maintaining the fragile peace between the beneficial – yet potentially dangerous – microbial world residing within the gut lumen and the rest of the host. It does this through constant sampling of the intestinal lumen, utilizing both innate and adaptive responses.

Neutrophils are recruited to the gut lamina propria and respond quickly in the event of bacterial invasion, engulfing and eliminating invading pathogens (37). Sepsis reduces the expression of cell surface adhesion molecules E-selectin and ICAM1 in the small intestine in the late, hypoinflammatory phase of sepsis, repressing neutrophil influx. When septic mice are given a SIRT1 inhibitor, they have increased endothelial expression of these adhesion molecules, as well as increased expression of PSGL-1 (a ligand of E-selection) on neutrophils (38). Notably, this is associated with improved survival, even when mice receive a SIRT1 inhibitor 24 hours after CLP, suggesting that sustained neutrophil influx to the intestine may play a role in sepsis mortality.

After bacteria either translocate spontaneously or are taken up from the gut lumen by antigen presenting cells, they are shuttled to the mesenteric lymph node. Antigens are then presented and bacterial specific IgA is generated against these bacteria (39). In addition, beyond interacting with the microflora, intestinal intraepithelial lymphocytes are tasked with maintenance of the gut epithelium, especially in response to inflammation. $\gamma\delta$ T cells work to help clear infection by having both innate and adaptive immune cell functions. While much of their function has yet to be elucidated, $\gamma\delta$ T cells have been shown to be involved in intestinal mucosal reparation by regulating mucin expression and promoting goblet cell function in the small intestine (40). Notably, depletion of $\gamma\delta$ T cells worsens mortality following CLP (41) while septic patients have a lower percentage of circulating $\gamma\delta$ T cells compared to healthy controls (42).

In addition to playing a vital role in interacting with the microbiome, the immune system also interacts with the gut epithelium. As sepsis progresses, patients have a marked upregulation of T cell co-inhibitory markers (43). Blockade of the T cell co-inhibitory molecule PD-1 and its ligand PD-L1 results in restoration of immune functionality across several cell lines and improves survival in multiple models of sepsis (44). Notably, PD-L1 is also upregulated in the gut epithelium following CLP and septic PD-L1^{-/-} mice have decreased intestinal permeability compared to WT mice (45).

Cross-talk between gut and other distant organs

As the motor of MODS, the gut can initiate and propagate injury distant from the intestine. The intestinal epithelium and pulmonary epithelium both are exposed to high concentrations of external antigens and thus, are centers in the initiation and maintenance of the inflammatory response. Notably, crosstalk exists in a bilateral fashion between the gut and the lung. *Staphylococcus aureus* pneumonia in the setting of surfactant protein knockout results in increased gut epithelial apoptosis, increased Bax/Bcl-2 expression and gut levels of TNF and IL-1 β (46). Gut-derived factors also travel from the intestine via the mesenteric lymph to cause ARDS, and ligation of the mesenteric lymph duct in the setting of critical illness prevents distant lung injury. Further, removal of toxic lymph from an injured animal can induce lung injury in a previously healthy animal (14). The gut microbiome can also influence lung pathophysiology. During pneumococcal pneumonia, there is worsened bacterial dissemination, inflammation, organ damage and mortality in mice depleted of the gut microbiota. However, FMT normalizes pulmonary bacterial counts and cytokines after pneumococcal pneumonia (47).

The liver is the organ in closest contact with the gut and is exposed to significant amounts of bacterial components and their metabolites via the portal circulation. There is emerging evidence that the microbiome is associated with acute and chronic liver diseases and that treating dysbiosis by prebiotics, probiotics and antibiotics can effectively treat numerous complications of severe liver disease seen in critically ill patients such as hepatic encephalopathy (48).

Critically ill patients frequently have acute kidney injury as a result of inflammation and hypoperfusion. Higher permeability of the mesenteric vascular bed directly causes intestinal tissue edema and gut barrier dysfunction, which, in turn, leads to a systemic inflammatory response which worsens acute kidney injury. Notably short-chain fatty acids produced by the microbiome improve kidney injury induced by ischemia-reperfusion by modulating the inflammatory process and ameliorating the effects of hypoxia by improving mitochondrial biogenesis (49). Further, microbiome products such as glycation end products, phenols, and indoles can accumulate in the setting of kidney injury and lead to further progression of renal damage (50).

Finally, emerging data suggests that the gut microbiome affects the central nervous system via a gut-brain axis, which influences anxiety, depression, cognition and visceral pain (51). As acute brain dysfunction such as delirium is unfortunately prevalent in critically ill

patients and is associated with worse outcomes, the microbiome represents a new target aimed at reversing this common organ dysfunction seen in the intensive care unit.

Conclusions

The gut is a highly complex system that under basal conditions maintains tight integration between its epithelium, microbiome and immune system to benefit host health in a myriad of ways. Unfortunately, all elements of the gut are dysregulated in critical illness, which can both drive and propagate distant organ dysfunction. Therapies aimed at restoring gut integrity, optimizing an effective immune response and reversing the pathological effects of dysbiosis represent exciting avenues of discovery and potential therapeutics for critically ill patients in the future.

Acknowledgments

1. None
2. **Financial support and sponsorship:** This work was supported by funding from the National Institutes of Health (GM072808, GM095442, GM104323, GM109779, GM113228)
3. **Conflicts of interest:** None to report

References

1. Carrico CJ, Meakins JL, Marshall JC, et al. Multiple-organ-failure syndrome. The gastrointestinal tract: the “motor” of MOF. *Arch Surg.* 1986 Feb; 121(2):196–208. [PubMed: 3484944]
2. Helander HF, Fandriks L. Surface area of the digestive tract - revisited. *Scand J Gastroenterol.* 2014 Jun; 49(6):681–9. [PubMed: 24694282]
- 3**. Sender R, Fuchs S, Milo R. Are We Really Vastly Outnumbered? Revisiting the Ratio of Bacterial to Host Cells in Humans. *Cell.* 2016 Jan 28; 164(3):337–40. This study describes the number of microbes living inside a human and refutes earlier commonly quoted data that there are many more microorganisms living inside a host than cells of host origin. [PubMed: 26824647]
4. Thome JJ, Yudanin N, Ohmura Y, et al. Spatial map of human T cell compartmentalization and maintenance over decades of life. *Cell.* 2014 Nov 6; 159(4):814–28. [PubMed: 25417158]
5. Reintam BA, Poeze M, Malbrain ML, et al. Gastrointestinal symptoms during the first week of intensive care are associated with poor outcome: a prospective multicentre study. *Intensive Care Med.* 2013 May; 39(5):899–909. [PubMed: 23370829]
6. Piton G, Belon F, Cypriani B, et al. Enterocyte damage in critically ill patients is associated with shock condition and 28-day mortality. *Crit Care Med.* 2013 Sep; 41(9):2169–76. [PubMed: 23782971]
- 7*. Piton G, Capellier G. Biomarkers of gut barrier failure in the ICU. *Curr Opin Crit Care.* 2016 Apr; 22(2):152–60. This review covers emerging biomarkers of intestinal barrier failure in critically ill patients and their potential utility. [PubMed: 26808138]
8. Klingensmith NJ, Coopersmith CM. The Gut as the Motor of Multiple Organ Dysfunction in Critical Illness. *Crit Care Clin.* 2016 Apr; 32(2):203–12. [PubMed: 27016162]
9. Mittal R, Coopersmith CM. Redefining the gut as the motor of critical illness. *Trends Mol Med.* 2014 Apr; 20(4):214–23. [PubMed: 24055446]
10. Coopersmith CM, Chang KC, Swanson PE, et al. Overexpression of Bcl-2 in the intestinal epithelium improves survival in septic mice. *Crit Care Med.* 2002 Jan; 30(1):195–201. [PubMed: 11902262]
11. Dominguez JA, Vithayathil PJ, Khailova L, et al. Epidermal growth factor improves survival and prevents intestinal injury in a murine model of pseudomonas aeruginosa pneumonia. *Shock.* 2011 Oct; 36(4):381–9. [PubMed: 21701422]

- 12**. Yoseph BP, Klingensmith NJ, Liang Z, et al. Mechanisms of Intestinal Barrier Dysfunction in Sepsis. *Shock*. 2016 Jul; 46(1):52–9. This study examines timing of gut barrier failure and mechanisms of gut barrier failure after both CLP and *Pseudomonas aeruginosa* pneumonia. Both models of sepsis generally share similar alterations in tight junction mediators; however, model-specific differences are also observed. [PubMed: 27299587]
13. Li Q, Zhang Q, Wang C, et al. Disruption of tight junctions during polymicrobial sepsis in vivo. *J Pathol*. 2009 Jun; 218(2):210–21. [PubMed: 19235836]
14. Deitch EA. Gut-origin sepsis: evolution of a concept. *Surgeon*. 2012 Dec; 10(6):350–6. [PubMed: 22534256]
15. Yi J, Slaughter A, Kotter CV, et al. Clean case of systemic injury: mesenteric lymph after hemorrhagic shock elicits a sterile inflammatory response. *Shock*. 2015 Oct; 44(4):336–40. [PubMed: 26196840]
16. Beck MK, Jensen AB, Nielsen AB, et al. Diagnosis trajectories of prior multi-morbidity predict sepsis mortality. *Sci Rep*. 2016 Nov 4.6:36624. [PubMed: 27812043]
- 17**. Lyons JD, Mittal R, Fay KT, et al. Murine Lung Cancer Increases CD4+ T Cell Apoptosis and Decreases Gut Proliferative Capacity in Sepsis. *PLoS ONE*. 2016; 11(3):e0149069. This study describes a model of pre-existing lung cancer prior to the onset of sepsis and compares it to previously healthy mice with the same septic insult. The cancer/septic mice have decreased gut proliferation as well as increased T cell apoptosis. [PubMed: 27018973]
18. Fox AC, Robertson CM, Belt B, et al. Cancer causes increased mortality and is associated with altered apoptosis in murine sepsis. *Crit Care Med*. 2010 Mar; 38(3):886–93. [PubMed: 20009755]
19. Yoseph BP, Breed E, Overgaard CE, et al. Chronic alcohol ingestion increases mortality and organ injury in a murine model of septic peritonitis. *PLoS ONE*. 2013; 8(5):e62792. [PubMed: 23717394]
- 20**. Klingensmith NJ, Yoseph BP, Liang Z, et al. Epidermal Growth Factor Improves Intestinal Integrity and Survival in Murine Sepsis Following Chronic Alcohol Ingestion. *Shock*. 2016 Jul 25. This study examines the impact of giving systemic epidermal growth factor to mice with 12 weeks of chronic alcohol ingestion prior to the onset of sepsis. Epidermal growth factor improves gut integrity and survival in alcohol/septic mice but the response is blunted in comparison to previously healthy/septic mice.
21. Turnbull IR, Buchman TG, Javadi P, et al. Age disproportionately increases sepsis-induced apoptosis in the spleen and gut epithelium. *Shock*. 2004 Oct; 22(4):364–8. [PubMed: 15377893]
22. Dominguez JA, Xie Y, Dunne WM, et al. Intestine-specific Mtp deletion decreases mortality and prevents sepsis-induced intestinal injury in a murine model of *Pseudomonas aeruginosa* pneumonia. *PLoS ONE*. 2012; 7(11):e49159. [PubMed: 23145105]
23. Liang Z, Xie Y, Dominguez JA, et al. Intestine-specific deletion of microsomal triglyceride transfer protein increases mortality in aged mice. *PLoS ONE*. 2014; 9(7):e101828. [PubMed: 25010671]
24. Xu Z, Knight R. Dietary effects on human gut microbiome diversity. *Br J Nutr*. 2015 Jan; 113(Suppl):S1–S5.
25. Ackerman J. The ultimate social network. *Sci Am*. 2012 Jun; 306(6):36–43. [PubMed: 22649992]
- 26**. Krezalek MA, Defazio J, Zaborina O, et al. The Shift of an Intestinal “Microbiome” to a “Pathobiome” Governs the Course and Outcome of Sepsis Following Surgical Injury. *Shock*. 2016 May; 45(5):475–82. This review is a comprehensive state of the art description of how dysbiosis occur following surgical illness and worsens outcome. [PubMed: 26863118]
27. Mariat D, Firmesse O, Levenez F, et al. The Firmicutes/Bacteroidetes ratio of the human microbiota changes with age. *BMC Microbiol*. 2009 Jun 9.9:123. [PubMed: 19508720]
- 28**. McDonald D, Ackermann G, Khailova L, et al. Extreme Dysbiosis of the Microbiome in Critical Illness. *mSphere*. 2016 Jul.1(4) This is the largest study of the microbiome to date (115 patients) in critical illness, demonstrating significant and persistent dysbiosis.
29. Hayakawa M, Asahara T, Henzan N, et al. Dramatic changes of the gut flora immediately after severe and sudden insults. *Dig Dis Sci*. 2011 Aug; 56(8):2361–5. [PubMed: 21384123]
30. Babrowski T, Romanowski K, Fink D, et al. The intestinal environment of surgical injury transforms *Pseudomonas aeruginosa* into a discrete hypervirulent morphotype capable of causing lethal peritonitis. *Surgery*. 2013 Jan; 153(1):36–43. [PubMed: 22862900]

- 31*. Manzanares W, Lemieux M, Langlois PL, Wischmeyer PE. Probiotic and synbiotic therapy in critical illness: a systematic review and meta-analysis. *Crit Care*. 2016 Aug 19;19:262. Meta-analysis of probiotics and synbiotics in critical care demonstrating a decrease in ventilator associated pneumonia and infections without an effect on mortality, length of stay or diarrhea. [PubMed: 27538711]
- 32**. Dickson RP. The microbiome and critical illness. *Lancet Respir Med*. 2016 Jan; 4(1):59–72. This is a comprehensive overview on the role of the microbiome in critical illness. [PubMed: 26700442]
33. Chapman BC, Moore HB, Overbey DM, et al. Fecal microbiota transplant in patients with *Clostridium difficile* infection: A systematic review. *J Trauma Acute Care Surg*. 2016 Oct; 81(4): 756–64. [PubMed: 27648772]
- 34*. Han S, Shannahan S, Pellish R. Fecal Microbiota Transplant: Treatment Options for *Clostridium difficile* Infection in the Intensive Care Unit. *J Intensive Care Med*. 2016 Oct; 31(9):577–86. This is an overview of the treatment fo *Clostridia difficile* infection in the ICU including fecal microbiota transplant. While FMT is still experimental inside the ICU, this review gives a list of possilbe indications. [PubMed: 26141116]
35. Li Q, Wang C, Tang C, et al. Successful treatment of severe sepsis and diarrhea after vagotomy utilizing fecal microbiota transplantation: a case report. *Crit Care*. 2015 Feb 9;19:37. [PubMed: 25881250]
36. Wei Y, Yang J, Wang J, et al. Successful treatment with fecal microbiota transplantation in patients with multiple organ dysfunction syndrome and diarrhea following severe sepsis. *Crit Care*. 2016 Oct 18;20(1):332. [PubMed: 27751177]
37. Hammer AM, Morris NL, Earley ZM, Choudhry MA. The First Line of Defense: The Effects of Alcohol on Post-Burn Intestinal Barrier, Immune Cells, and Microbiome. *Alcohol Res*. 2015; 37(2):209–22. [PubMed: 26695746]
38. Vachharajani VT, Liu T, Brown CM, et al. SIRT1 inhibition during the hypoinflammatory phenotype of sepsis enhances immunity and improves outcome. *J Leukoc Biol*. 2014 Nov; 96(5): 785–96. [PubMed: 25001863]
39. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. *Cell*. 2014 Mar 27; 157(1):121–41. [PubMed: 24679531]
40. Kober OI, Ahl D, Pin C, et al. gammadelta T-cell-deficient mice show alterations in mucin expression, glycosylation, and goblet cells but maintain an intact mucus layer. *Am J Physiol Gastrointest Liver Physiol*. 2014 Apr 1; 306(7):G582–G593. [PubMed: 24503767]
41. Costa MF, de Negreiros CB, Bornstein VU, et al. Murine IL-17+ Vgamma4 T lymphocytes accumulate in the lungs and play a protective role during severe sepsis. *BMC Immunol*. 2015 Jun 3;16:36. [PubMed: 26037291]
42. Galley HF, Lowes DA, Thompson K, et al. Characterisation of gamma delta (gammadelta) T cell populations in patients with sepsis. *Cell Biol Int*. 2015 Feb; 39(2):210–6. [PubMed: 25196852]
43. Shubin NJ, Monaghan SF, Heffernan DS, et al. A B and T lymphocyte attenuator expression on CD4+ T-cells associates with sepsis and subsequent infections in ICU patients. *Crit Care*. 2013 Nov 29;17(6):R276. [PubMed: 24289156]
44. Chang K, Svabek C, Vazquez-Guillamet C, et al. Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis. *Crit Care*. 2014 Jan 4;18(1):R3. [PubMed: 24387680]
- 45**. Wu Y, Chung CS, Chen Y, et al. Novel Role for Programmed Cell Death Receptor Ligand-1 (PD-L1) in Sepsis-Induced Intestinal Dysfunction. *Mol Med*. 2016 Oct 25.:22. This study demonstrates that PD-L1 is upregulated on the gut epithelium in sepsis and PD-L1 knockout animals have improved intestinal permeability.
- 46*. Du X, Meng Q, Sharif A, et al. Surfactant Proteins SP-A and SP-D Ameliorate Pneumonia Severity and Intestinal Injury in a Murine Model of *Staphylococcus Aureus* Pneumonia. *Shock*. 2016 Aug; 46(2):164–72. This study demonstrates that Surfactant proteins SP-A and SP-D play an important role in mediating gut epithelial apoptosis in *Staphylococcus aureus* pneumonia, as sepsis-induced cell death is increased after knocking out these proteins. [PubMed: 26849628]

- 47**. Schuijt TJ, Lankelma JM, Scicluna BP, et al. The gut microbiota plays a protective role in the host defence against pneumococcal pneumonia. *Gut*. 2016 Apr; 65(4):575–83. This study demonstrates that depleting the gut microbiota worsens bacterial dissemination and mortality following pneumococcal pneumonia. However, bacterial counts and cytokines are normalized following FMT. [PubMed: 26511795]
48. Tilg H, Cani PD, Mayer EA. Gut microbiome and liver diseases. *Gut*. 2016 Oct 8.
49. Andrade-Oliveira V, Amano MT, Correa-Costa M, et al. Gut Bacteria Products Prevent AKI Induced by Ischemia-Reperfusion. *J Am Soc Nephrol*. 2015 Aug; 26(8):1877–88. [PubMed: 25589612]
50. Khoury T, Tzuket K, Abel R, et al. The gut-kidney axis in chronic renal failure: A new potential target for therapy. *Hemodial Int*. 2016 Sep 16.
- 51*. Kennedy PJ, Cryan JF, Dinan TG, Clarke G. Kynurenine pathway metabolism and the microbiota-gut-brain axis. *Neuropharmacology*. 2017 Jan; 112(Pt B):399–412. This paper reviews the connections between the gut microbiome and the brain. While not focused on critical care, this outlines an axis that is frequently overlooked and could have significant clinical importance. [PubMed: 27392632]

Key Points

1. All elements of the gut – the epithelium, microbiome and immune system – are markedly dysregulated in critical illness
2. Alterations to the gut induced by critical illness cause organ damage distant from the intestine by a variety of mechanisms
3. Critical illness induces increased gut epithelial apoptosis and hyperpermeability.
4. Critical illness induces dysbiosis, wherein the microbiome loses diversity and changes to a more pathogenic flora